Skip to main content
SpringerLink
Log in

Aflibercept/brolucizumab/ranibizumab

Lack of efficacy and eye disorders: 4 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Abdin AD, et al. First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration. Frontiers in Pharmacology 13: 30 May 2022. Available from: URL: http://doi.org/10.3389/fphar.2022.860784

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aflibercept/brolucizumab/ranibizumab. Reactions Weekly 1918, 29 (2022). https://doi.org/10.1007/s40278-022-20486-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-20486-6

Search

Navigation